|SAGA SURGICAL AB
|Funding from Vinnova
|SEK 300 000
|March 2017 - August 2017
Purpose and goal
Saga Surgical is a Medtech Company aiming at reducing infectious complications due to needle punctures. Our main focus is prostate biopsies. The VINNOVA grant has enabled us to: 1) design and produce a working prototype prostate biopsy gun for our needle. 2) do market research for the prostate biopsy market and alternative markets, such as amniocentesis and prostetic joint punctures.
Expected results and effects
1) Inital safety and endurance tests of the new biopsy system (gun+needle) are positive. Biopsy sampling of animal tissue has been succesful althogh there is room for further improvment in biopsy quality. 2) A market segment analysis of prostate biopsy needles has been made. 3) Field studies have been made in a hospital setting and preclinical bacterial studies have been performed comparing todays products for amniocentesis and joint punctures to our new needle. Results favor our product.
Planned approach and implementation
Our main focus remains reduction of sepsis due to transrectal prostate biopsies. We are continuing development of an injection needle and a biopsy needle + gun for transrectal prostate biopsy. We are planning an human pilot in late 2017 followed by a major human study starting 2018. Our secondary target at this time is to help reduce fetal mortality due to infections caused by amniocentesis.